Bone marrow derived mesenchymal stem/stromal cells transduced with full length human TRAIL repress the growth of rhabdomyosarcoma cells in vitro

Haematologica

Volumn 96, Issue 3, 2011, Pages 21-22

  Barti Juhasz, Helga ^a   Mihalik, Rudolf ^a,b   Nagy, Katalin ^a   Grisendi, Giulia ^c   Dominici, Massimo ^c   Petak, Istvan ^a,d  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d KPS Medical Biotechnology and Healthcare Service Limited   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADOPTIVE IMMUNOTHERAPY; ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CANCER INHIBITION; CYTOKINE INDUCED KILLER CELL; CYTOTOXICITY; HUMAN; IN VITRO STUDY; LETTER; MESENCHYMAL STEM CELL; PROTEIN EXPRESSION; RHABDOMYOSARCOMA; SARCOMA CELL; STROMA CELL;

BONE MARROW CELLS; CELL COUNT; CELL LINE, TUMOR; COCULTURE TECHNIQUES; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GROWTH INHIBITORS; HUMANS; MESENCHYMAL STEM CELLS; MOLECULAR TARGETED THERAPY; PLASMIDS; RHABDOMYOSARCOMA; STROMAL CELLS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSDUCTION, GENETIC;

EID: 79952344549     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.036822     Document Type: Letter

References (12)

1. Kuci S, Rettinger E, Voss B, Weber G, Stais M, Kreyenberg H, et al. Efficient lysis of rhabdomyosarcoma cells by cytokine-induced killer cells: implications for adoptive immunotherapy after allogeneic stem cell transplantation. Haematologica. 2010;95(9):1579-86.
2. Petak I, Douglas L, Tillman DM, Vernes R, Houghton JA. Pediatric rhabdomyosarcoma cell lines are resistant to Fas-induced apoptosis and highly sensitive to TRAIL-induced apoptosis. Clin Cancer Res. 2000;6(10):4119-27.
3. Izeradjene K, Douglas L, Delaney A, Houghton JA. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells. Clin Cancer Res. 2004;10(19):6650-60.
4. Petak I, Vernes R, Szucs KS, Anozie M, Izeradjene K, Douglas L, et al. A caspase-8-independent component in TRAIL/Apo-2Linduced cell death in human rhabdomyosarcoma cells. Cell Death Differ. 2003;10(6):729-39.
5. Mahalingam D, Szegezdi E, Keane M, Jong S, Samali A. TRAIL receptor signalling and modulation: are we on the right TRAIL? Cancer Treat Rev. 2009;35(3):280-8.
6. Herbst RS, Eckhardt SG, Kurzrock R, Ebbinghaus S, O'Dwyer PJ, Gordon MS, et al. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol. 2010;28(17):2839-46.
7. Loebinger MR, Eddaoudi A, Davies D, Janes SM. Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res. 2009;69(10):4134-42.
8. Kim SM, Lim JY, Park SI, Jeong CH, Oh JH, Jeong M, et al. Gene therapy using TRAIL-secreting human umbilical cord bloodderived mesenchymal stem cells against intracranial glioma. Cancer Res. 2008;68(23):9614-23.
9. Sasportas LS, Kasmieh R, Wakimoto H, Hingtgen S, van de Water JA, Mohapatra G, et al. Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci USA. 2009;106(12):4822-7.
10. Ciavarella S, Dominici M, Dammacco F, Silvestris F. Mesenchymal Stem Cells: A New Promise in Anticancer Therapy. Stem Cells Dev. 2011;20(1):1-10.
11. Grisendi G, Bussolari R, Cafarelli L, Petak I, Rasini V, Veronesi E, et al. Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy. Cancer Res. 2010;70(9):3718-29.
12. Muller I, Kordowich S, Holzwarth C, Isensee G, Lang P, Neunhoeffer F, et al. Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation. Blood Cells Mol Dis. 2008;40(1):25-32.